Primary brain tumour
Drug research and approvals for primary brain tumour: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 69 studies of primary brain tumour are recruiting on ClinicalTrials.gov, and Health Canada has authorized 5 drug trials for it since 2013.
- Recruiting worldwide: 69
- Trials authorized in Canada: 5
- FDA orphan approvals: 0
- EU medicines: 0
Recruiting Now
Newest start dates first, of 69 recruiting on ClinicalTrials.gov ↗- Evaluating Biomarkers of Cognitive Dysfunction in Patients With CancerNCT07226466 · Not reported · University of California, San Francisco · starts Nov 2, 2026
- IL-8 Receptor Modified Patient-Derived Activated CD70 CAR T Cell Therapy in Adults With Brain MetastasesNCT07569263 · Phase 1 · University of Florida · starts Oct 13, 2026
- Pharmacoscopy for Patients With Refractory Primary Brain TumorsNCT06804655 · Phase 2 · University of Zurich · starts Sep 11, 2026
- An Exercise Intervention for Improving Mental and Physical Health in Patients With Primary Brain Tumors and Their…NCT07278440 · Not applicable · OHSU Knight Cancer Institute · starts Aug 24, 2026
- A Study of 177Lu-DTPA-Omburtamab in Children and Adolescents With Brain Cancer or Cancer That Has Spread to the Central…NCT07698899 · Phase 1 · Memorial Sloan Kettering Cancer Center · starts Jul 2, 2026
- Belvarafenib for CNS Efficacy in Patients With BRAF-Altered Solid TumorsNCT07688356 · Phase 2 · Samsung Medical Center · starts Jun 15, 2026
- BEAT-Breast: Trial of DE-iPTV in Patients With Primary Breast Cancer With Brain Metastases Who Are Not Suitable for…NCT06611306 · Not applicable · Imperial College London · starts Jun 1, 2026
- Virus-Based Gene Therapy (AdV-HSV1-TK and AdV-Flt3L) in Combination With Valacyclovir for the Treatment of Pediatric…NCT06914479 · Phase 1 · University of Michigan Rogel Cancer Center · starts May 22, 2026
- Periodontal Disease in Rare Renal Disorders (PERIO-RA-RE)NCT07575347 · Not reported · Stefan Lujinschi · starts May 4, 2026
- Inflammation in Primary and Secondary Malignancies of the Central Nervous System Using [C-11]-CS1P1NCT07462507 · Phase 2 · Washington University School of Medicine · starts Apr 16, 2026
Trials Authorized in Canada
Newest first; search them all in Canada trials| Mar 25, 2026 | Vigor: vorasidenib as maintenance treatment after first-line chemoradiotherapy in idh-mutant grade 2 or 3 astrocytoma: a placebo-controlled triple-blind,…VORASIDENIB (S095032, AG-881) | CANADIAN CANCER TRIALS GROUP, CANCER RESEARCH INSTITUTE, QUEEN'S UNIVERSITY | Ongoing |
| Aug 25, 2023 | Phase 2 study of the mek inhibitor mektovi® (binimetinib) for the treatment of pediatric adamantinomatous craniopharyngiomaBINIMETINIB | COLLABORATIVE NETWORK FOR NEURO-ONCOLOGY CLINICAL TRIALS (CONNECT) | Ongoing |
| Mar 11, 2022 | A safety and preliminary efficacy trial of pembrolizumab (mk- 3475) in children with recurrent, progressive or refractory diffuse intrinsic pontine glioma…KEYTRUDA | PEDIATRIC BRAIN TUMOUR CONSORTIUM | Closed |
| Feb 15, 2022 | Phase III randomized double-blind placebo-controlled trial of metformin for cognitive recovery and white matter growth in paediatric patients with a brain…METFORMIN | HOSPITAL FOR SICK CHILDREN | Ongoing |
| Dec 22, 2016 | 18f-dopa pet imaging: an evaluation of biodistribution and safety18F-DOPA | UNIVERSITY OF ALBERTA | Pending |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA